HIV-1 Virus-Like Particles Produced by Stably Transfected

D
eveloping a safe and effective vaccine to control human immunodeficiency virus type 1 (HIV-1) pandemic is a major global health priority. The encouraging results from a recent phase III study (RV144) of a combination vaccine regimen conducted in Thailand have created optimism that a preventive vaccine can be developed, although the efficacy of that regimen was judged to be marginal, short-lived, and not sufficient to be useful at the population level (40) . Thus, an optimal vaccine may require a component that elicits broadly neutralizing antibodies that are capable of binding to the envelope spikes on the virion surface, as well as memory T cells that recognize multiple T cell epitopes on viral proteins (31) .
HIV-1 virus-like particles (VLP), because they display authentic envelope spikes on the particle surface, may be developed into such a vaccine component to elicit both neutralizing antibody and memory T cell responses (11, 57, 58) . Indeed, immunization of HIV-1 VLP has been shown to generate promising immune responses in animals. For example, Hammonds et al. demonstrated that in a guinea pig model the breadth of neutralizing antibody response elicited with HIV-1 VLP produced by stably transfected 293T cells was enhanced compared to subunit protein of the same HIV-1 isolate (16). Buonaguro et al. (5) showed that systemic and mucosal cross-subtype neutralizing antibody responses were elicited in mice with HIV-1 VLP produced by insect cells infected with recombinant baculoviruses (RB). McBurney et al. (30) showed that HIV-1 VLP produced by transfected COS cells elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent envelope vaccines. However, in macaque challenge models definitive proof of protection has not been clearly demonstrated. Immunization with simian immunodeficiency virus (SIV)/HIV VLP elicited an anamnestic response to HIV-1 gp120, which correlated with accelerated clearance of SHIV (34) ; immunization with single cycle SIV elicited broad SIVspecific T cell responses and significantly reduced viral loads after intravenous SIV challenge (22) ; repeated vaccination with VSV-G-pseudotyped SIV VLP significantly reduced peak viremia after mucosal SIV challenge, but persistent suppression of viral load was not achieved (25) ; and vaccination with chemically inactivated SIV particles elicited both SIV envelope-specific binding and neutralizing antibody responses and significantly reduced viral loads after intravenous homologous SIV challenge but failed to resist subsequent heterologous SIV challenge (26) . In contrast, immune responses elicited by VLP alone or by heterologous poxvirus-VLP prime-boost did not protect macaques from SHIV or SIV challenge (33, 50) .
Although HIV-1 VLP as immunogens have shown great promise, in one way or another the production of HIV-1 VLP by current systems has many limitations. For example, yeast (42) or mammalian 293T (16) cells, COS cells (30) , and Vero cells (36) transiently cotransfected with DNA plasmids encoding HIV-1 envelope and Gag proteins can produce enough HIV-1 VLP for small animal studies but not enough for large animals and humans. Because of this, attempts have been made to establish stable mammalian cell transfectants for HIV-1 VLP production, in which genes encoding HIV-1 Gag and envelope proteins were driven by a tetracycline-inducible promoter (16, 17) . Although this approach yields more HIV-1 VLP, the amount is still too low to be practical for large animals and humans.
Using insect cells infected with RB yields much higher amounts of HIV-1 VLP (37, 41) . The HIV-1 VLP produced by infected insect cells elicits both humoral and cellular immune responses (5) . However, there are three major drawbacks to using insect cells infected with RB for HIV-1 VLP production. First, culture supernatants contain both HIV-1 VLP and RB. Routine purification procedures such as gradient centrifugation or ultrafiltration cannot strictly discriminate HIV-1 VLP from RB. As a result, a significant amount of live baculovirus is present in the HIV-1 VLPcontaining fractions (17, 41) . Contamination of HIV-1 VLP preparations with live baculovirus is important with regard to immunogenicity and regulatory issues. Because of this, as an alternative to the baculovirus system, piggyback transposition that expressed HIV-1 Gag protein was developed to create transgenic insect cell lines for continuous HIV-1 Gag VLP production (27) . Second, HIV-1 gp160 precursor envelope proteins are not cleaved in insect cells infected with RB (17) , although the effect of uncleaved gp160 on immunogenicity has yet to be investigated. Third, since insect cells infected with RB are short-lived, a new infection is required each time a new batch of HIV-1 VLP is going to be produced. Because of this, the amount and the quality of HIV-1 VLP could vary among different batches.
Therefore, to overcome the limitations associated with current HIV-1 VLP production systems, in the present study we developed a novel strategy to produce HIV-1 VLP using stably transfected Drosophila melanogaster Schneider 2 (S2) cells. S2 cells have been widely used to produce ectropic proteins, including HIV-1 envelope proteins (8, 21) . HIV-1 envelope precursor gp160 has been shown to be properly cleaved in S2 cells during its biogenesis (4, 21) . We hypothesized that S2 cells, due to their high efficiency in expressing ectropic proteins and proper cleavage of HIV-1 envelope precursor, can be used to produce HIV-1 VLP. Furthermore, because the system uses only plasmids, HIV-1 VLP produced by this system will have no recombinant virus contamination. Finally, stably transfected S2 cells can grow to a high viable cell density, resulting in large amount of HIV-1 VLP production in culture supernatants. For these reasons, stably transfected S2 cells may overcome many limitations and drawbacks in HIV-1 VLP production by the current systems.
To test this hypothesis, we cotransfected S2 cells with plasmids encoding an envelope glycoprotein (consensus B or consensus C), a Rev-independent Gag (Pr55) protein, and a Rev protein, along with a pCoBlast selection marker. For the comparison, we also cotransfected S2 cells with plasmids encoding a Rev-independent Gag and a pCoBlast marker or with plasmids encoding gp120 (consensus B or consensus C), a Rev protein and a pCoBlast marker. After the stable cell transfectants were generated, a limiting dilution assay was performed to establish stably transfected S2 clones. After stably transfected clones were established, the expression, process, and glycosylation of envelope proteins, the production, morphology, and antigenicity of HIV-1 VLP, and the immunogenicity of HIV-1 VLP in mice were carefully evaluated.
MATERIALS AND METHODS
Cell lines. Drosophila S2 cells were provided by Vincent Deubel at the Institut Pasteur of Shanghai and cultured in complete Express Five SFM medium (i.e., Express Five SFM medium supplemented with 10% fetal bovine serum [FBS] , 100 U of penicillin/ml, 100 U of streptomycin/ml, and 100 mg of L-glutamine/liter) at 28°C without CO 2 . Every 3 or 4 days, the cells were split at a density of 10 6 cells per ml. The human embryonic kidney cell line 293T was purchased from Invitrogen Life Technologies and maintained in complete Dulbecco modified Eagle medium (DMEM; i.e., high-glucose DMEM supplemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, penicillin [100 U/ml], streptomycin [100 g/ml]) plus G418 (500 g/ml; Invitrogen Life Technologies). TZM-bl cells were obtained from the NIH AIDS Research and Reference Reagent Program (ARRRP; Germantown, MD) (9, 38) . The human CD4 ϩ T cell line CEMss-CCR5 was generated as described previously (54) . These cells were maintained in complete DMEM.
Chronically HIV-1-infected CEMss-CCR5 cells were prepared by incubating CEMss-CCR5 cells with an HIV-1 strain AD8 at a multiplicity of infection (MOI) of 1 overnight. After the infection, cells were maintained in complete DMEM. Periodically, HIV-1 replication and cell surface expression of HIV-1 envelope protein were measured (see below).
Antibodies and pooled HIV-1 patient sera. Human anti-gp120 or gp41 antibodies b12, 2G12, PG16, and 4E10 and mouse anti-Gag p24 antibody (183-H12-5C) were obtained from the ARRRP. Pooled HIV-1 patient plasmas were provided by Ping Zhong at the Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China. Mouse antigp120 antibody (catalog no. 4301) and sheep anti-gp120 C5 capture antibody (catalog no. D7324) were purchased from Advanced Bioscience Laboratory, Inc. (Silver Spring, MD), and Aalto BioReagents (Dublin, Ireland), respectively. Human anti-gp120 antibody VRC01 and human anti-H5 hemagglutinin (HA) antibody 100F4 were produced and purified in our laboratory by using stably transfected S2 clones as described previously (53) . Allophycocyanin (APC)-conjugated anti-CD8, PerCP-conjugated anti-CD4, fluorescein isothiocyanate (FITC)-conjugated antigamma interferon (anti-IFN-␥), phycoerythrin (PE)-Cy7-conjugated anti-tumor necrosis factor alpha (anti-TNF-␣), and purified anti-CD49d and anti-CD28 antibodies were purchased from BD Bioscience (Mountain View, CA).
Gene constructs. cDNA sequence encoding HIV-1 Rev-independent Gag p55 (M1-10) (44) was generated by recursive PCR (39) , cloned into a TA vector (Invitrogen), and sequenced as described previously (59) . The correct insert was inserted into EcoRI and NotI sites of a constitutive S2 expression vector pAc5.1/V5-His (Invitrogen). The resulting construct was designated pAC-Gag(Pr55) (Fig. 1A) .
cDNA encoding consensus B and consensus C HIV-1 gp160 envelope proteins without a signal peptide were PCR amplified using HIV-1 consensus B and consensus C envelope genes (23, 24 ; generously provided by B. H. Hahn at the University of Alabama) as templates and inserted into the EcoRI and XhoI sites of an inducible S2 expression vector pMT/BiP/ V5-His (Invitrogen). The resulting constructs were designated pMT/BiPgp160 (consensus B and consensus C), respectively (Fig. 1A) .
cDNA sequence encoding HIV-1 Rev was amplified using a pZeoSV/ Rev as a template and inserted into the EcoRI and NotI sites of an inducible expression vector pMT/V5-His (Invitrogen). The resulting construct was designated as pMT-Rev (Fig. 1A) .
cDNA encoding consensus B and consensus C HIV-1 gp120 envelope proteins without a signal peptide were inserted into the BamHI and XhoI sites of an inducible S2 expression vector pMT/BiP/V5-His. The resulting constructs were designated pMT/BiP-gp120/V5-His (consensus B and consensus C), respectively.
For the mammalian expression, cDNA encoding consensus B and consensus C HIV-1 gp120 envelope proteins with a signal peptide or HIV-1 Gag(Pr55) were inserted into mammalian expression vector pCMV/R (3). The resulting plasmids were designated as CMV/R-gp120 (consensus B and consensus C) and CMV/R-Gag(Pr55), respectively. Plasmid was produced at the concentration of 1 mg/ml in sterile water and found to be predominantly supercoiled by gel electrophoresis with endotoxin levels below 1.5 EU/mg DNA.
Generation of stable Drosophila S2 cell clones. To generate stable S2 transfectants to produce HIV-1 VLP, S2 cells were cotransfected with 9.5 g of pAc-Gag(Pr55), 4.75 g of pMT/Bip-gp160 (consensus B or consensus C), and 4.75 g of pMT-Rev, along with 1 g of selection vector pCoBlast, which contains the blasticidin resistance gene (Invitrogen) using a calcium phosphate precipitation method (47) . After overnight incubation, the cells were washed once with phosphate-buffered saline (PBS) and cultured in complete Express Five SFM medium. After 72 h, blasticidin (Invitrogen) at the final concentration 25 g/ml was added, and stable S2 transfectants were generated in 2 to 3 weeks.
To generate stable S2 clones, a limiting dilution assay was performed as described earlier (54) . Briefly, 1.5 ϫ 10 2 S2 transfectants were mixed with 10 6 parental S2 cells (feeder layer cells) in 10 ml of Drosophila Schneider 2 medium supplemented with 10% FBS, 100 U of penicillin/ml, 100 U of streptomycin/ml, and 100 mg of L-glutamine/liter. A 100-l portion of cell mixture was added to each well in 96-well plates, followed by incubation at 28°C for 2 days. Blasticidin at a final concentration of 25 g/ml was then added to the culture medium. After 3 weeks, single clones were isolated for further expansion. The stably transfected S2 clones were induced by 5 M CdCl 2 , and the expression of HIV-1 envelope and Gag proteins in culture supernatants was analyzed by Western blot analysis (see below). The S2 clones that produced the most HIV-1 VLP (consensus B and consensus C) were selected for HIV-1 VLP production (see below).
To generate stably transfected S2 cells expressing soluble gp120, S2 cells were cotransfected with 9.5 g of pMT/BiP-gp120/V5-His (consensus B or consensus C) and 9.5 g of pMT-Rev, along with 1 g of selection vector pCoBlast, and selected with blasticidin as described above. After stable transfectants were established, a limiting dilution assay was performed as described above. The S2 clones that produced the highest amount of gp120 were selected for gp120 production (see below).
Production of HIV-1 VLP and soluble gp120 by S2 clones. Wave bioreactor 20/50EHT systems with a Wavepod process control unit (GE Healthcare) were used to grow S2 clones in fed-batch culture for HIV-1 VLP and soluble gp120 production as described before (53) . Briefly, 6 ϫ 10 8 cells of the S2 clones in 300 ml of complete Express Five SFM medium were inoculated into a 2-liter cell bag and cultured at 28°C without CO 2 . At 5, 7, and 8 days after the initial culture in the Wave bioreactor, 300, 200, and 200 ml, respectively, of fresh complete Express Five SFM medium were added. At 8 days after the initial culture, CdCl 2 at a final concentration of 5 M was added into culture medium to induce the expression of HIV-1 envelope proteins. Three days after the induction, the culture supernatants were harvested, clarified by centrifugation at 6,000 ϫ g for 30 min at 4°C, and filtered through a 0.45-m-pore-size filter. Filtered supernatants were concentrated 5-fold using QuixStand benchtop system incorporated with a 50,000 NMWC hollow-fiber cartridge (Model UFP-50-C-4MA). HIV-1 VLP in concentrated supernatant was pelleted by ultracentrifugation through a20% sucrose cushion, resuspended in PBS, and stored in aliquots at Ϫ80°C until further use (see below). During 11 day's fed-batch culture, a small aliquot of cell suspension was collected every 24 h. The number and viability of cells were determined by trypan blue exclusion assay. The amount of HIV-1 VLP, as measured by HIV-1 gp120 and Gag p55, was determined (see below). Soluble gp120 in concentrated supernatants were purified by Ni-NTA column according to the manufacturer's instructions (Invitrogen). The amount and purity of the proteins was quantified by a BCA assay (Pierce) and determined by 10% SDS-PAGE, followed by Coomassie blue staining.
Western blot analysis. To test HIV-1 envelope and Gag protein expression, S2 clones were induced with 5 M CdCl 2 for 3 days. Culture supernatants were harvested, precipitated by using trichloroacetic acid (TCA), and dissolved in PBS. Samples were separated through 10% SDS-PAGE and transferred onto polyvinylidene difluoride membranes (PVDF; Millipore). The membranes were blocked in a solution of Trisbuffered saline containing 5% nonfat dry milk and 0.05% Tween 20 and subsequently probed with an anti-Gag p24 antibody and with the indicated antibodies specific for HIV-1 gp120 and gp41. Antigens were visualized with an alkaline phosphatase (AP)-conjugated anti-mouse IgG antibody according to the manufacturer's instructions (Promega).
To test the incorporation of HIV-1 envelope and Gag proteins into VLP, the VLP-containing supernatants were harvested, clarified by centrifugation at 6,000 ϫ g for 30 min at 4°C, filtered through a 0.45-mpore-size filter, loaded onto a 20% sucrose cushion, and ultracentrifuged at 20,000 rpm for 2.5 h at 4°C in a SW28 rotor (Beckman Coulter, Fullerton, CA). The pellets were resuspended and fractionated through a 25 to 65% sucrose density gradient at 25,000 rpm for 16 h at 4°C in a SW41 rotor (Beckman Coulter). Twelve fractions (1 ml of each) were collected from the top to the bottom of the gradient, and the density of each fraction was measured. The samples were then TCA precipitated, separated by 10% SDS-PAGE, and transferred onto PVDF membranes. The presence of HIV-1 Gag and envelope proteins in unfractionated and fractionated samples were detected as described above.
To test the mammalian expression of plasmids CMV/R-gp120 (consensus B and consensus C) and CMV/R-Gag(Pr55), 293T cells were transiently transfected with plasmids encoding soluble consensus B and consensus C HIV-1 gp120 envelope proteins or Gag(Pr55). Two days after transfection, supernatants were harvested, pelleted by ultracentrifugation, separated by 10% SDS-PAGE, and transferred onto PVDF membranes. The presence of HIV-1 gp120 or Gag(Pr55) proteins was detected by the indicated antibodies against gp120 or Gag p24.
To quantify the amount of Gag p55 in supernatants produced by S2 clones in fed-batch culture, Western blot and densitometry analyses were performed as reported by Lynch et al. (27) . Briefly, culture supernatants were collected daily during 11 days of fed-batch culture (see above) and loaded onto 4 to 12% Bis-Tis gel (Invitrogen), along with a serially 2-folddiluted p24 standards (starting at 40 ng; Aalto BioReagents), and then transferred onto PVDF membranes. The membranes were blocked in a solution of TBST containing 5% nonfat dry milk and subsequently probed with an anti-Gag p24 antibody. Antigens were visualized with a horseradish peroxidase (HRP)-conjugated anti-mouse IgG antibody (MultiSciences) and EZ-ECL substrate (Thermo). Gag concentrations were estimated by comparing calculated densities of the p55 bands in experimental samples and p24 standards using Quantity One software (Bio-Rad). Consistent with what was previously reported (27), we also found that HIV-1 VLP concentrations determined by calculating densities of the p55 band on Western blots is a more reliable indicator of actual VLP concentration in the sample than using p24 enzyme-linked immunosorbent assay (ELISA) quantification (Y. Song et al., data not shown).
ELISA. To estimate the amount of HIV-1 envelope incorporation into HIV-1 VLP, 96-well EIA/RIA flat-bottom plates (Costar) were coated overnight with 100 ng of anti-HIV-1 gp120 C5 capture antibody. The plates were blocked with PBS containing 5% bovine serum albumin (BSA) for 1 h at 37°C. The VLP-containing culture supernatants, concentrated supernatants, or a serially diluted purified gp120 (serving as standards) in assay diluent (10% BSA and 0.5% Triton X-100 in PBS) were added to anti-gp120 antibody-coated 96-well plates, followed by incubation at 37°C for 2 h. The plates were then washed five times with PBST buffer (0.05% Tween 20 in PBS). Anti-gp120 antibody (catalog no. 4301) at a 1:2,000 dilution was then added, followed by incubation for another 1 h. HRP-conjugated goat anti-mouse IgG (Chemicon) at a 1:5,000 dilution was added. Colorimetric analysis was performed using a TMB substrate kit (Pierce), and the absorbance was read at 450 nm by a spectrophotometer (BioTek Instruments, Winooski, VT).
To determine the antigenicity of HIV-1 VLP, a similar sandwich ELISA was performed with 10-fold-diluted human anti-gp120 and gp41 antibodies (b12, VRC01, 2G12, PG16, and 4E10) and control antibody (100F4), followed by HRP-conjugated goat anti-human Ig(HϩL) (IgMϩIgGϩIgA; SBA) at a 1:2,000 dilution as a secondary antibody. Colorimetric analysis was performed as described above.
To test total IgG, IgG1, and IgG2a antibody responses against consensus B and consensus C gp120, 96-well EIA/RIA flat-bottom plates were coated with 100 ng of the respective consensus B or consensus C gp120 proteins/well at 4°C overnight. The plates were blocked with PBS containing 5% BSA at 37°C for 1 h, followed by incubation with serially diluted mouse serum samples or pooled human plasmas at 37°C for 2 h. Plates were washed five times with PBST buffer and incubated with HRP-conjugated anti-mouse IgG (1:5,000) or anti-human IgG (1:2,000), antimouse IgG1 (1:500), or anti-mouse IgG2a (1:500) antibodies, respectively, at 37°C for 30 min. The wells were washed five times with PBST buffer. Colorimetric analysis was performed as described above. Endpoint titers were determined as the last reciprocal serial serum or plasma dilution at which the absorption at 450 nm was greater than the mean plus 2 standard deviations (SD) of the background signals generated by preimmune serum samples.
Characterization of glycosylation of HIV-1 envelope proteins produced by S2 clones. The glycosylation pattern of HIV-1 gp120 produced by stably transfected S2 cells was measured using DIG glycan differentiation kit according to the manufacturer's instruction (catalog no. 11210238001; Roche). Briefly, purified HIV-1 gp120 produced by stably transfected S2 cells, along with internal controls supplied with the kit, were separated using 10% SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked in 20 ml of blocking solution sup-plied by the kit for 30 min. After two washes with TBS, membranes were incubated with digoxigenin-labeled lectins: GNA (Galanthus nivalis agglutinin), SNA (Sambucus nigra agglutinin), DSA (Datura stramonium agglutinin), MAA (Maackia amurensis agglutinin), and PNA (peanut agglutinin), respectively, for 1 h. After two washes with TBS, a glycosylation pattern was visualized with an AP-conjugated anti-digoxigenin antibody according to the manufacturer's instructions.
To deglycosylate envelope protein produced by S2 cells, 1 g of soluble gp120 and either HIV-1 VLP-or wild-type HIV-1-containing culture supernatants equivalent to 1 g of total proteins were denatured by heating at 100°C for 10 min in the presence of 0.5% SDS and 40 mM dithiothreitol. After cooling, 1 l of PNGase F or Endo-H (New England Biolabs, Ipswich, MA) was added, and the mixture was incubated in 1ϫ G7 or G5 reaction buffers (New England Biolabs) at 37°C for 1 h. Subsequently, the samples were subjected to protein gel electrophoresis and Western blot analyses using anti-HIV-1 gp120 antibody (catalog no. 4301) as described above.
Cryo-EM tomography. To purify HIV-1 VLP for a cryo-electron microscopy (cryo-EM) study, culture supernatants produced by stably transfected S2 clones were harvested and clarified by low-speed centrifuge at 6,000 ϫ g for 30 min at 4°C, passed through a 0.45-m-pore-size filter (Fisher), loaded onto a 20% sucrose cushion, and ultracentrifuged at 25,000 rpm for 2 h using an SW28 rotor. The pellets were resuspended with PBS, loaded onto 25 to 65% linear sucrose gradient, and ultracentrifuged at 25,000 rpm for 16 h (SW41 rotor). VLP-containing fractions were pooled and pelleted by ultracentrifugation at 25,000 rpm for 2 h (SW41 rotor). The pellets were resuspended with PBS, loaded onto a 30 and 45% nonlinear sucrose gradient, and ultracentrifuged at 110,000 ϫ g for 3 h (MLS-50 rotor). Two fuzzy bands, one close to the top of sucrose gradient (upper band) and the other at the sucrose interface (lower band), were collected, diluted in PBS, and passed through a 0.2-m-pore-size, lowprotein-binding, nonpyrogenic syringe filter (catalog no. PN4612; Pall). The samples were then pelleted by ultracentrifugation at 110,000 ϫ g for 2 h (MLS-50 rotor), resuspended in 20 l of PBS, and stored at Ϫ80°C.
To observe VLP by cryo-EM tomography, 3.5 l of upper-and lowerband samples were loaded onto a 300-mesh R2/1 Quantifoil Holey grid (Quantifoil Micro Tools, GmbH, Jena, Germany) for 1 min, blotted for 4 s with a filter paper, and rapidly vitrified into liquid ethane using an FEI Vitrobot Mark IV. The grid was transferred to a Gatan 626 Cryoholder (Gatan, Pleasanton, CA) and examined under low-dose conditions on an FEI Tecnai 20 electron microscope operated at 200 kV. Micrographs were recorded on a Gatan Ultrascan 1,000 charge-coupled device camera in an FEI Tecnai F20 electron microscope operated at 200 kV with a magnification of ϫ38,000 and a defocus of ϳ2.5 m. Cryo-EM tomography was performed at an FEI 300 kV Titan Krios cryo-EM equipped with a Gatan UltraScan 4000 (model 895) 4Kϫ4K-pixel charge-coupled device. Singleaxis tilt series were collected at ϫ47,000 magnification using 2Kϫ2K CCD mode around a single axis at a 2°increment between Ϫ62°and ϩ60°at a pixel size of 0.38 nm. The defocus was set at Ϫ3 to Ϫ6 m, and the cumulative dose was ϳ72 e/Å 2 . Immunization and sampling. All animal protocols were approved by the Institutional Animal Care and Use Committee at the Institut Pasteur of Shanghai (approval A2011014). Female BALB/c mice (Mus musculus) at the age of 6 to 8 weeks were purchased from the Shanghai Institutes of Biological Sciences Animal Center and housed in microisolator cages ventilated under negative pressure with HEPA-filtered air and a 12/12-h light/ dark cycle. For the immunization, mice were randomly divided into two groups. Group 1 was intramuscularly (i.m.) injected of both hind legs with a total of 200 l of PBS (pH 7.4). Group 2 was i.m. primed twice with 150 g of three plasmids encoding consensus B and consensus C HIV-1 gp120 proteins and Rev-independent HIV-1 Gag (50 g of each) and then subcutaneously (s.c.) boosted twice with a mixture of HIV-1 VLP (consensus B and consensus C) equivalent to 5 g of gp120 plus 5 g of phosphorothioate CpG oligodeoxynucleotides (CpG-ODN 1826 [5=-TCC ATG ACG TTC CTG ACG TT-3=]) (18) . The HIV-1 VLP used for boosting contained a mixture of Gag-alone particles versus Env-Gag particles, which was likely in a 1-to-1 ratio, because the optical densities of the two fuzzy bands (an upper band containing Gag-alone particles versus a lower band containing Env-Gag particles) collected after the ultracentrifugation in 30 and 45% nonlinear sucrose gradient were very similar (see above). The DNA prime was done on day 0 and 28 and the HIV-1 VLP/CpG boost was done on day 56 and 84. Seven days before prime and 10 days after boost, blood samples were collected by retro-orbital plexus puncture. Serum samples were collected, heat inactivated at 56°C and stored in aliquots at Ϫ20°C. Ten days after the boost spleens were harvested and splenocytes were isolated by Ficoll-Hiquac gradient centrifugation, depleted of erythrocytes by treatment with NH 4 Cl (0.1 M, pH 7.4). The cells were then washed with PBS and resuspended in complete RPMI 1640 medium (i.e., RPMI 1640 supplemented with 10% inactivated FBS, 100 U of penicillin/ ml, 100 U of streptomycin/ml, and 100 mg of L-glutamine/liter) for intracellular cytokine staining (see below).
HIV-1 and 10A1 pseudotypes and a single-cycle infectivity assay. HIV-1 and 10A1 pseudotypes were generated and a single-cycle infectivity assay was performed as described previously (32, 54) .
FACS analysis. To study the cell surface expression of the HIV-1 envelope, chronically HIV-1-infected CEMss-CCR5 cells (see above) were incubated with postimmune sera, sera from PBS control mice, or pooled HIV-1-infected patient sera for 45 min on ice. The cells were then washed twice with fluorescence-activated cell sorting (FACS) buffer (PBS containing 1% BSA and 0.02% NaN 3 ) and stained with PE-conjugated antimouse or anti-human IgG antibody (Sigma) for another 45 min on ice. The cells were then washed twice with FACS buffer and fixed with 1% formaldehyde in 0.5 ml of FACS buffer. FACS analysis was performed on a BD LSRII flow cytometer (BD Biosciences).
ADCC assay. A rapid fluorometric antibody-dependent cell-mediated cytotoxicity (ADCC) assay was performed as previously described (14, 45) . Briefly, 5,000 HIV-1-infected CEMss-CCR5 target cells were doubly labeled with 5 M PKH-26 (Sigma-Aldrich) and 0.5 M carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes). Labeled target cells were resuspended in RPMI 1640 medium containing 10% FBS and incubated with pre-and postimmune sera from PBS control and immunized mice, naive mouse sera (negative control), or pooled HIV-1 patient sera (positive control) at a final dilution of 1:50 in a 96-well microplate for 30 min at room temperature. Splenocytes (effector cells) from naive mice were added at a 50:1 effector/target cell (E:T) ratio. The plates were centrifuged for 5 min at 400 ϫ g to promote cell-cell interactions and then incubated for 4 h at 37°C in 5% CO 2 . The cells were washed twice with PBS and then fixed in 3.7% (vol/vol) paraformaldehyde-PBS for flow cytometry. A total of 50,000 nongated events in duplicate wells were acquired within 18 h using a BD LSRII flow cytometer. The data were analyzed using FlowJo (Tree Star, Inc.). The percent ADCC killing was determined by back-gating on the PKH-26 high population of target cells that lost the CFSE viability dye and subtracted the nonspecific effect by preimmune sera. Unstained and single-stained targets were included in every experiment to compensate for single-stained CFSE and PKH-26 emission.
ADCVI assay. The target and effector cells used for the antibodydependent cell-mediated viral inhibition (ADCVI) assay were the same HIV-1-infected CEMss-CCR5 cells and naive splenocytes used for ADCC (see above). Target cells (5,000) were washed to remove cell-free virus. Effector cells (naive splenocytes) were added to target cells at an E:T ratio of 20:1. Pre-and postimmune sera from PBS control and immunized mice, naive mice sera (negative control) or pooled HIV-1-infected patient sera (positive control) were added to target and effector cells to achieve a final dilution of 1:50. Control wells lacking sera but containing effector cells and viral replication control wells lacking both sera and effector cells were included. Two days later, supernatants were collected, and Gag p24 was measured by ELISA (Zeptometrix). The percent inhibition due to ADCVI was calculated relative to pooled preimmune mice sera as follows: percent inhibition ϭ 100[(1 Ϫ p24 post )/p24 pre ], where p24 post and p24 pre are the concentrations of p24 in supernatant fluid from wells containing a source of post-or preimmune sera, respectively. Individual serum samples were assayed in triplicate and in two separate assays. In general, the values from the two independent assays were in close agreement with each other.
Intracellular cytokine staining. A total of 2 ϫ 10 6 splenocytes from immunized and control mice were seeded into complete RPMI 1640 and stimulated with two mixtures of peptides (2 g of each peptide/ml) as previously described (30) , one mixture containing peptides derived from HIV-1 envelope protein and the other from Gag protein, as well as 5 g of anti-mouse CD28 and 5 g of anti-mouse CD49d for 6 h at 37°C and 5% CO 2 . A Golgi plug (BD Pharmingen) was added during the final 4 h of incubation. The cells were then stained with anti-mouse CD16/32 (Fc block) antibody, followed by surface staining with PerCP-conjugated anti-CD4 and APC-conjugated anti-CD8 antibodies. The cells were then fixed, permeabilized with Cytofix Cytoperm (BD Pharmingen), and stained with FITC-conjugated anti-IFN-␥ and PE-Cy7-conjugated anti-TNF-␣. A total of 10 6 cells per sample were acquired on a BD LSRII flow cytometer, and the FACS data were analyzed using FlowJo software.
Statistics. Analyses were performed with GraphPad Prism v5.0. An unpaired Student t test was used to compare the two data sets. Correlation between the ADCC and the ADCVI was assessed by using the exact Spearman rank correlation method. All P values are two-tailed.
RESULTS
HIV-1 envelope and Gag proteins were properly produced, processed, and incorporated into VLP. To generate stably transfected S2 clones that produce large amounts of HIV-1 VLP, we cotransfected Drosophila S2 cells with the plasmids pACGag(Pr55), pMT/BiP-gp160 (consensus B or consensus C), pMTRev, and pCoBlast, in which genes encoding HIV-1 envelope and Rev proteins were driven by an inducible pMT promoter, while the gene encoding HIV-1 Gag(Pr55) was driven by a constitutive pAC promoter (Fig. 1A) . After the stable transfectants were established, a limiting dilution assay was performed to generate stably transfected S2 clones. Figure 1B shows that in supernatants from S2 clone VB2, but not from parental S2 cells, HIV-1 Gag p55 was readily detected with or without induction, whereas without induction a faint gp120 was detected, while after induction the expression of gp120 increased dramatically. Figure 1C shows that after induction both gp41 and gp160 of HIV-1 envelope proteins were detected by antibody 4E10, but only gp120 was detected by antibody VRC01, indicating that although precursor HIV-1 envelope gp160 was properly cleaved into gp120 and gp41, because the high level of expression of HIV-1 gp160 in stable S2 transfectants, only over 60% of gp160 was cleaved by cellular endopeptidase(s) during their biogenesis through the Golgi apparatus. Similar studies on the induction of envelope protein and cleavage of gp160 into gp120 and gp41 were also observed in S2 clone VC1 (that expressed consensus C HIV-1 envelope protein) (Yang et al., data not shown).
To test the incorporation of envelope and Gag proteins into HIV-1 VLP, S2 clone VB2 was induced with CdCl 2 , and the supernatants were harvested, concentrated, and then fractionated through a 25 to 65% sucrose gradient. The envelope and Gag proteins in each fraction were detected with a mixture of two mouse antibodies against gp120 and Gag p24. As a control, supernatants from S2 cells stably transfected with pAC-Gag(Pr55) alone were also harvested, concentrated, and fractionated through the same sucrose gradient. As shown in Fig. 1D , Gag proteins derived from S2 cells transfected with pAC-Gag(Pr55) alone were peaked in the fractions with buoyant density between 1.10 and 1.14, whereas both gp160 and gp120 and Gag proteins derived from S2 clone cotransfected with pAC-Gag(Pr55) and pMT/Bip-gp160 were peaked in the fractions with buoyant density between 1.15 and 1.19 (Fig. 1E) , probably indicating that both uncleaved gp160 and cleaved gp120/gp41 were incorporated into the VLP and that the difference in the 160-kDa gp160 band shown in Fig. 1E , but not in Fig. 1C , was because two different anti-HIV-1 gp120 antibodies (VRC01 and 4301) were used to detect HIV-1 glycoproteins. In Western blot, antibody VRC01 only reacted with gp120, whereas antibody 4301 reacted with both gp120 and gp160. A similar study was performed in the stable S2 clone VC1 with similar results (Yang et al., data not shown). Thus, taken together, these results clearly indicate that in the S2 clones the HIV-1 envelope proteins are properly induced and cleaved and both envelope and Gag are incorporated into HIV-1 VLP.
Glycosylation of envelope proteins produced by S2 clones. To test glycosylation of envelope proteins on HIV-1 VLP produced by S2 clone VB2, we first performed deglycosylation assays with the N-endoglycosidase PNGase F and Endo H. For a comparison, glycosylation of soluble gp120 produced by S2 clone B5 (that expressed consensus B gp120) and wild-type HIV-1 (Bru-3) were also tested. PNGase F removes all types of N-linked oligosaccharides from glycoproteins, whereas Endo H cleaves the chitobiose core of high-mannose and hybrid oligosaccharides from Nlinked glycoproteins. Figure 2A shows that without PNGase F or Endo H treatment, a 120-kDa band was detected by anti-gp120 antibody in soluble gp120, as well as in HIV-1 VLP, whereas with PNGase F treatment, gp120 bands of soluble gp120 and HIV-1 VLP were reduced to 70-kDa band. In contrast, with Endo H treatment, the gp120 bands of soluble gp120 and HIV-1 VLP were reduced to about 74 and 85 kDa, respectively. A similar, but not identical, deglycosylation pattern was seen in envelope proteins of wild-type HIV-1 virions with PNGase F or Endo H treatment ( Fig.  2A) . Thus, these results not only revealed that soluble gp120 and envelope protein on HIV-1 VLP produced by S2 clones are Nlink-glycosylated but also highlighted some differences in N-linked glycosylation between soluble gp120 and envelope proteins on HIV-1 VLP, even though these envelope glycoproteins were both produced by clones derived from the same S2 cells.
To further test glycosylation patterns, soluble gp120 produced by S2 clone B5 were probed with the lectins GNA, SNA, MAA, PNA, and DSA, which recognize different sugar moieties (see Materials and Methods). As shown in Fig. 2B , a large amount of gp120 produced by the S2 clone was detected by GNA, and a small amount was detected by PNA and DSA, but not by SNA and MAA, indicating that, on a given HIV-1 envelope glycoprotein produced by S2 clones, there are probably more high-mannose glycans and fewer hybrid and complex forms.
Quantification of HIV-1 VLP produced by S2 clones. To test the cell growth and HIV-1 VLP production by S2 clones, S2 clones were grown in fed-batch culture using the Wave bioreactor for a total of 11 days. At 8 days after the initial fed-batch culture, CdCl 2 was added to induce HIV-1 envelope expression (see Materials and Methods). Figure 3A shows the growth of a representative S2 clone VB2 in the fed-batch culture. Starting with 300 ml of seed cell suspension, 300, 200, and 200 ml of fresh culture medium were added on day 5, 7, and 8, respectively, and the cell density increased from 2 ϫ 10 6 cells per ml on day 0 to 2.2 ϫ 10 7 cells per ml on day 11. By so doing, the total viable cell numbers grew about 37-fold from 6 ϫ 10 8 cells on day 0 to 2.2 ϫ 10 10 cells on day 11 (Fig. 3B) . Figure 3C shows that while the amount of Gag p55 in the supernatants grew steadily and reached 9.5 g/ml on day 11, the amount of gp120 in the supernatants before the CdCl 2 induction was very low, but after the induction the amount of gp120 increased dramatically and reached 4.2 g/ml on day 9 and 7.5 g/ml on day 11. Similar cell growth and HIV-1 VLP production were also observed in another S2 clone VC1 (Song et al., data not shown).
Morphology and spike number on HIV-1 VLP produced by S2 clones. To assess the morphology of the HIV-1 VLP produced by S2 clones, HIV-1 VLP in culture supernatants were concentrated and purified (see Materials and Methods), and the morphology and spikes on the surface of purified HIV-1 VLP were analyzed by cryo-EM and electron tomography. Figure 4A (Table 1) , which is slightly larger but comparable to those of the native SIV and HIV-1 virions we measured in the similar cryo-EM tomograms (109 Ϯ 14 nm and 110 Ϯ 8 nm for SIV and HIV-1, respectively) (62) . It is also consistent with the measurements of the SIV and HIV-1 virions in the negative-stain electron tomograms (61) . At this time, we do not really know what accounts for the heterogeneity in the size of the VLP. However, it may be due to the lack of HIV-1 protease in VLP to process immature p55 Gag. Interestingly, particles collected from the upper band did not exhibit any spikes on the HIV-1 VLP surface (Fig. 4A) , whereas on the surfaces of particles collected from the lower band, envelope spikes were readily observed (Fig. 4B ). Electron tomography with selected 12 particles collected from the lower band showed an average of 17 Ϯ 2 spikes per particle (ranging from 13 to 20 spikes) (Fig. 4C and Table 1 ). Furthermore, like those observed on the surfaces of the SIV or HIV-1 virions (62), no discrete periodic distances between spikes on the surface of HIV-1 VLP were observed (Fig. 4D) .
Antigenicity of HIV-1 envelope glycoproteins produced by S2 clones. To test the antigenicity of HIV-1 envelope glycoproteins produced by stably transfected S2 clones, we performed three sets of experiments with a panel of broadly neutralizing antibodies-2G12, b12, VRC01, PG16, and 4E10 (6, 7, 52, 55, 60, 63)-as well as the control antibody 100F4 antibody (53) . The antige- nicity results of HIV-1 envelope glycoproteins are summarized in Table 2 .
In the first experiment, we compared the antigenicities of HIV-1 envelope glycoproteins on the cell surface between the human kidney cell line 293T transiently transfected with CMV/Rgp160 (consensus B) and the S2 clone VB2 that expressed the same gp160 (consensus B). Figure S1 in the supplemental material shows that on the surfaces of transduced 293T cells the HIV-1 envelope glycoproteins were recognized by all broadly neutralizing antibodies (2G12, b12, VRC01, PG16, and 4E10) but not by the control antibody 100F4, whereas on the surfaces of S2 clone HIV-1 envelope glycoproteins were recognized by antibodies 2G12, b12, VRC01, and 4E10 but not by PG16 and the control antibody 100F4.
In the second experiment, we measured the antigenicity of HIV-1 VLP by Western blot analysis. Figure S2 in the supplemental material shows that HIV-1 VLP was only recognized by the broadly neutralizing antibodies VRC01, 2G12, and 4E10 but not by b12, PG16, and control antibody 100F4.
In the third experiment, we measured the antigenicity of HIV-1 VLP by sandwich ELISA using serially diluted antibodies (see Materials and Methods). Figure S3 in the supplemental material shows that HIV-1 VLP was only bound by the broadly neutralizing antibodies 2G12, b12, and VRC01 in a dose-dependent manner, but not by PG16 and 4E10 nor by control antibody 100F4. These findings, taken together, lead us to conclude that, except for antigenic epitope PG16, all other broadly neutralizing antigenic epitopes 2G12, b12, VRC01, and 4E10 tested are preserved on spikes of HIV-1 VLP produced by S2 clones.
ELISA-binding antibody responses elicited by DNA-VLP prime-boost. In our initial studies on the immunogenicity of HIV-1 VLP, we found that HIV-1 VLP produced by S2 clones was immunogenic even without a supplement of any adjuvant. However, priming with DNA and boosting with HIV-1 VLP enhanced immunogenicity (Yang et al., data not shown), a finding similar to that reported by Buonaguro et al. (5) . In addition, we demonstrated that a heterologous DNA-VLP prime-boost elicited a superior neutralizing antibody response and protection in mice against HPAI H5N1 virus than homologous DNA-DNA or VLP-VLP vaccination (10) . Therefore, in the present study, the immunogenicity of HIV-VLP produced by stably transfected S2 clones was evaluated in the heterologous DNA-VLP prime-boost setting. Specifically, BALB/c mice were i.m. primed twice with three plasmids CMV/R-gp120 (consensus B and consensus C) and CMV/ R-Gag(Pr55) and s.c. boosted twice with a mixture of HIV-1 VLP expressing consensus B and consensus C envelope proteins in the presence of CpG. BALB/c mice injected with PBS were used as controls. Serum samples were collected before and after immunization, and splenocytes were harvested after sacrifice. No animals showed any signs of toxicity, and all remained healthy up to the end of the immunization protocol.
To evaluate HIV-1 envelope-specific serum antibody titers, ELISA was performed on microwell plates coated with consensus B and consensus C gp120, respectively. For the comparison, pooled HIV-1 patient plasmas were used. The plasmas were pooled by eight plasma samples selected from more than 800 samples of HIV-1 B=C recombinant virus-infected individuals in China. In our unpublished study, these eight individual plasmas broadly neutralized various subtypes of HIV-1 strains (Yang et al., data not shown). Figure 5A and B show that both mouse immune sera and pooled human plasmas exhibited very high endpoint titers, with average titers of 1.77 ϫ 10 7 in mouse immune sera and 2.37 ϫ 10 7 in human plasmas against consensus B gp120 and average titers of 5.43 ϫ 10 6 in mouse immune sera and 3.67 ϫ 10 7 in human plasmas against consensus C gp120. Figure 5C and D show that high titers of specific serum IgG1 against consensus B or C gp120 were elicited in the immunized group. At 1:10 4 dilutions, optical density (OD) values ranging from 0.7 to 1.7 were detected against consensus B gp120 and from 0.8 to 1.6 against consensus C in the immunized group. Compared to the OD values detected in the PBS control group the difference is very significant (P Ͻ 0.0001 for consensus B gp120; P Ͻ 0.0001 for consensus C gp120). Figure 5E and F show that high titers of specific serum IgG2a against consensus B or consensus C gp120 were elicited in the immunized group. At 1:10 4 dilutions, OD values ranging from 0.1 to 0.8 were detected against consensus B gp120 and from 0.1 to 0.7 against consensus C in the immunized group. Compared to the OD values detected in the PBS control group the difference is statistically significant (P ϭ 0.0371 for consensus B gp120 and P ϭ 0.0111 for consensus C gp120). Thus, we conclude that a heterologous DNA-VLP prime-boost elicits very high titers of ELISAbinding total IgG, IgG1, and IgG2a responses against both consensus B and consensus C envelope proteins.
Neutralizing antibody responses elicited by DNA-VLP prime-boost. To test neutralization activity of the immune sera, an HIV-1 pseudotype-based neutralization (PN) assay was performed against a panel of HIV-1 pseudotypes, as well as 10A1 control. The retroviral envelope 10A1 recognizes either Ram-1 or Glvr-1 as a receptor for cell entry (32) and was used here as a negative control. The panel of HIV-1 pseudotypes consists of HIV-1 envelopes derived from clade A (Q168), clade B (consensus B, AD8, HXBc2, and Yu2), clade B= (CNE11), clade C (consensus C), and CRF01_AE (CNE3). Figure 6A shows the neutralization activity of immune sera at 1:50 dilutions against the pseudotype panel. As expected, compared to pseudotypes alone, immune sera from all six immunized mice exhibited no neutralization activity against control 10A1 pseudotype. Compared to the neutralization activity against the control 10A1 pseudotype, there was no significant neutralization activity of the immune sera against the AD8 pseudotype. In contrast, the immune sera from six immunized mice exhibited statistically significant neutralization activity against Q168, consensus B, HxBc2, Yu2, consensus C, CNE3, and CNE11 pseudotypes. Among them, on average, there were 60 and 40% neutralization activities against autologous consensus B and consensus C pseudotypes, respectively, and 51, 42, 41, 36, and 21% neutralization activities against heterologous CNE11, HXBc2, CNE3, Yu2, and Q168 pseudotypes, respectively.
To further test the neutralization activity, the immune sera of individual immunized mice were titrated against HIV-1 pseudotypes expressing consensus B, consensus C, CNE11, and CNE3 envelope proteins (Fig. 6B) . On average, at a 1:20 dilution 70% 
a ELISA, enzyme-linked immunosorbent assay; WB, Westernblotting; FACS, fluorescence-activated cell sorting.
neutralization activity against consensus B, 54% neutralization activity against consensus C, 60% neutralization activity against CNE11, and 55% neutralization activity against CNE3 were detected, and at a 1:60 dilution the neutralization activity decreased to 50% neutralization activity against consensus B, 20% neutralization activity against consensus C, 40% neutralization activity against CNE11, and 35% neutralization activity against CNE3. The preimmune sera from immunized mice did not show any neutralization activity. With the same pooled human plasmas, we also titrated their neutralizing antibody activity against HIV-1 pseudotypes expressing consensus B, consensus C, CNE3, and CNE11. As shown in Fig. S4 in the supplemental material, these highly selected, pooled human plasmas exhibited neutralizing antibody activities comparable to or even higher than those of the mouse immune sera shown in Fig. 6B . Thus, we conclude that a DNA-VLP prime-boost elicits neutralizing antibody responses against a number of autologous and heterologous envelope proteins. However, their potency and breadth still need to be improved.
ADCC and ADCVI responses elicited by DNA-VLP primeboost. To test whether immune sera elicited with DNA-VLP prime-boost could mediate ADCVI, we first infected CEMss-CCR5 cells with HIV-1 AD8 strain and 15 days later measured virus replication by HIV-1 Gag p24 ELISA and stained cell surface expression of HIV-1 envelope protein using pooled HIV-1 patient sera, followed by FACS. We found that HIV-1 replicated well in infected CEMss-CCR5 cells (Yang et al., data not shown) and that HIV-1 envelope proteins were expressed on the surfaces of infected cells (right panel of Fig. 7A ). We then stained cell surface expression of HIV-1 envelope protein using sera from PBS control mice and immune sera elicited with DNA-VLP prime-boost. The left and middle panels of Fig. 7A show that immune sera elicited with DNA-VLP prime-boost mice, but not from PBS control, recognized HIV-1 envelope proteins on the surfaces of infected cells.
We next investigated whether immune sera could mediate ADCC using AD8-infected cells as target cells and naive mouse splenocytes as effector cells. Figure 7B shows that at a serum dilution of 1:50, an ADCC activity ranging from 5 to 12% was ob- served in immune sera from all six immunized mice, whereas no ADCC activity was observed in the sera from all six PBS control mice. The difference was also highly statistically significant (P ϭ 0.0002). The experiment was repeated twice with similar results.
ADCVI of immune sera was also investigated using the same AD8-infected cells and naive mouse splenocytes as target and effector cells, respectively. Figure 7C shows that at a serum dilution of 1:50, an ADCVI activity ranging from 15 to 40% was observed in immune sera from all six immunized mice, whereas no ADCVI activity was observed in the sera from all six PBS control mice. The difference was highly statistically significant (P ϭ 0.006). The experiment was repeated twice with similar results. Figure 7D shows that there was a positive correlate between the percent killing by ADCC and the percent inhibition by ADCVI (r ϭ 0.9161) when the sera from all immunized and PBS control mice were analyzed.
CD8 T cell responses elicited by DNA-VLP prime-boost. To test whether DNA-VLP prime-boost could elicit HIV-1 envelope and Gag-specific T cell responses, splenocytes from DNA-VLP prime-boost and PBS control mice were assayed against envelope or Gag peptide mixtures using intracellular cytokine staining for IFN-␥ and TNF-␣. Figure 8A shows that compared to CD8 T cells from PBS control mice, CD8 T cells from DNA-VLP prime-boost mice exhibited statistically significant peptide-specific responses against envelope peptides. On average, 0.35% of CD8 T cells secreted IFN-␥ and 0.39% of CD8 T cells secreted TNF-␣. In contrast, no CD8 T cell response against envelope peptides was observed in the splenocytes from all six PBS control mice. The differences were highly statistically significant (P Ͻ 0.0001 for both IFN-␥ and TNF-␣). Figure 8B shows that compared to CD8 T cells from PBS control mice, CD8 T cells from DNA-VLP prime- ϩ T cells that produce IFN-␥ and TNF-␣ are shown. Splenocytes from mice (n ϭ 6 per group) immunized with a DNA-VLP prime-boost or mice (n ϭ 6 per group) from PBS control were assessed, and the immune responses were measured 10 days after the final boost. boost mice exhibited statistically significant peptide-specific responses against Gag peptides. On average, 0.06% of CD8 T cells secreted IFN-␥ and 0.07% of CD8 T cells secreted TNF-␣. In contrast, no CD8 T cell response against Gag peptides was observed in splenocytes from all six PBS control mice. The differences were highly statistically significant (P ϭ 0.009 for IFN-␥ and P ϭ 0.0226 for TNF-␣). Thus, we conclude that the DNA-VLP prime-boost elicits both HIV-1 envelope and Gag-specific CD8 T cell responses.
DISCUSSION
In the present study, we developed stably transfected Drosophila S2 cell clones to produce HIV-1 VLP and demonstrated that in 1 liter of culture supernatant the amount of HIV-1 VLP produced by S2 cell clones is equivalent to 7.5 mg of gp120 and 9.5 mg of Gag p55 (Fig. 3C) , which is comparable to that produced by insect cells infected with RB (5, 41) and much higher than those produced by mammalian cells (16, 17, 30, 36, 42) . The high HIV-1 VLP production is mainly due to the fact that stably transfected S2 clones could grow to a much higher viable cell density than mammalian cells. In the present study, stably transfected S2 clones in the fedbatch culture using a Wave bioreactor grew to 2.2 ϫ 10 7 cells per ml without significantly compromising cell viability ( Fig. 3A and  B) . In our study with other S2 clones, we found that using Wave bioreactor stably transfected S2 clones in perfusion culture could grow to 10 8 cells per ml without compromising cell viability (53) . Therefore, there is still room to improve HIV-1 VLP production by our stably transfected S2 clones. In addition, unlike HIV-1 VLP produced by insect cells infected with RB, envelope proteins in HIV-1 VLP produced by stably transfected S2 clones were properly cleaved into gp120 and gp41 (Fig. 1C) . Moreover, unlike HIV-1 VLP produced by insect cells infected with RB, culture supernatants produced by stably transfected S2 clones are not contaminated with recombinant viruses. Thus, compared to current expression systems, stably transfected S2 clones truly have several distinct advantages for HIV-1 VLP production.
In the present study, we also demonstrated that mice primed with plasmids expressing HIV-1 gp120 and Gag and boosted with HIV-1 VLP produced by stably transfected S2 clones in the presence of CpG exhibited both anti-envelope antibody responses (see Fig. 5, 6 , and 7) and envelope and Gag-specific CD8 T cell responses (see Fig. 8 ). Anti-HIV-1 envelope antibody responses include ELISA binding, neutralizing, ADCC, and ADCVI. The percentage of killing by ADCC and the percentage of inhibition by ADCVI are positively correlated (Fig. 7D) . The protective role of envelope and Gag-specific CD8 T cells in the control of SIV replication has been inferred by several studies in macaques (29, 43, 48) . The protective role of neutralizing antibodies has also been demonstrated in SHIV-infected macaque models through passive immunization (1, 28, 49) . However, the in vivo mechanism of protection through passive immunization of antibody b12 was, in part, Fc␥R mediated (19) . Indeed, vaccine studies in macaques (2, 15, 20, 56) and analyses of sera from HIV-1-infected individuals (13, 46) have shown an inverse correlation between the levels of ADCC or ADCVI and virus load. Thus, although exact correlates of protection against HIV-1 are still not fully established, if we take into account the correlates of immune protection against other viral pathogens, as well as understanding the immune components that control HIV-1 in vivo, the consensus view now is that a highly effective vaccine will need to elicit coordinated antibody and T cell responses (31) . Thus, the demonstration that DNA-VLP prime-boost could elicit both antibody and T cell responses in mice and that antibody responses include ELISA binding, neutralizing, ADCC, and ADCVI in the present study makes HIV-1 VLP produced by stably transfected S2 clones a promising vaccine component.
Although the present study focused on DNA prime and VLP/ CpG boost to evaluate immunogenicity of HIV-1 VLP, in our preliminary study we compared immunogenicity between DNA prime and VLP/CpG boost versus DNA prime and soluble gp120/ CpG boost in mice. We found that although DNA-VLP/CpG elicited higher, but not statistically significant, ELISA-binding antibody and CD8 T cell responses than DNA-gp120/CpG, neutralizing antibody responses elicited by DNA-VLP/CpG vaccination are significantly higher than those elicited by DNAgp120/CpG (Yang et al. data not shown). We also compared immunogenicity between DNA-DNA, VLP/CpG-VLP/CpG, and DNA-VLP/CpG in mice. We found that DNA-VLP/CpG elicited significantly higher ELISA binding and neutralizing antibody responses than those elicited by DNA-DNA and VLP/CpG-VLP/ CpG vaccination (Yang et al., data not shown).
In the present study we also show that envelope proteins in HIV-1 VLP produced by stably transfected S2 clones are recognized by several broadly neutralizing antibodies 2G12, b12, VRC01, and 4E10 but not by PG16 (Table 2 and see Fig. S1 , S2, and S3 in the supplemental material). We found that whereas antibody 2G12 could bind to envelope proteins on both transfected 293 T cells and S2 cells, antibody PG16 could only bind to envelope proteins on the surfaces of transfected 293 T cells but not of transfected S2 cells (Table 2 and see Fig. S1 in the supplemental material). Antibody 2G12 recognizes terminal dimannose (Man␣1,2Man) moieties on oligomannose glycans (7), and antibody PG16 recognizes a conformational epitope that is dependent on glycosylation at specific variable-loop N-linked sites (12, 52) . The difference in PG16 recognition of envelope proteins expressed on the surfaces of transfected 293T cells and S2 cells, therefore, is likely due to the heterogeneity in glycosylation. Recently, six new human broadly neutralizing antibodies-PGT 125, 126, 127, 128, 130, and 131-that bind specifically to the Man8/9 glycans on gp120 have been reported (35, 51) . Among them, PGT 128, the broadest of these antibodies, neutralizes more than 70% of globally circulating viruses and is, on average, an order of magnitude more potent than PG16 and VRC01 (51) . PGT 128 was found to bind to two conserved glycans and a short ␤-strand segment of the gp120 V3 loop (35); therefore, it will be interesting to test whether these new antibodies can recognize glycans on envelope proteins produced by stably transfected S2 clones, which was found to be mainly glycosylated in a high-mannose form with a few in complexes and hybrids ( Fig. 2A and B) .
Finally, careful analysis of the morphology of HIV-1 VLP produced by stably transfected S2 cell clones also points out an inherited shortcoming in the vector system we used in the present study. We found that because in the vector system the Gag gene was under a constitutive promoter and the envelope gene was under an inducible promoter, there are two kinds of HIV-1 VLP in supernatants. One kind of HIV-1 VLP produced before cells were induced by CdCl 2 is mainly present in the upper band of nonlinear sucrose gradient and does not have spikes on its surface (Fig. 3C  and 4A ) and has lower buoyant density between 1.10 and 1.14 ( Fig. 1D) , while the other kind produced after cells were induced by CdCl 2 is present only in the lower band of the nonlinear sucrose gradient and does have spikes on its surface (Fig. 3C and 4B ) and has a higher buoyant density between 1.15 and 1.18 (Fig. 1E) . Importantly, using cryo-EM and electron tomography methods, we were able to analyze spikes on the surfaces of a dozen of representative spike-containing HIV-1 VLP and found that average 17 spikes per particle are present on particle surface after the purification (Table 1) , which is similar to what was previously reported in wild-type HIV-1 particles (62). Furthermore, like those observed on the surfaces of SIV or HIV-1 virions (62), we also did not find discrete periodic distances between spikes on the surfaces of HIV-1 VLP (Fig. 4D) as one may have expected if spike placement reflected an underlying geometry of matrix and capsid Gag structure. Furthermore, since we did observe that both uncleaved gp160 and cleaved gp120/gp41 comigrated with HIV-1 Gag in a sucrose gradient (Fig. 1E) , the spikes on the surface of HIV-1 VLP observed in Fig. 4C probably represent both uncleaved gp160 and cleaved gp120/gp41, which cannot be distinguished by the current reconstruction with cryo-EM tomography. Therefore, further refinement of vector system to express Gag and envelope proteins under both constitutive and both inducible promoters, as well as production, induction, and purification protocols, are needed to maximize the yield of envelope spikes containing HIV-1 VLP.
